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Abstract 
Introduction: Relapsed histologically aggressive non-Hodgkin's lymphoma (NHL) has a poor prognosis; relapsed patients who respond 
to second-line chemotherapy have a better outcome after BMT, while those who do not respond to second line or are unfit for BMT have 
a worse prognosis and new treatments are needed. Angiogenesis is increased in aggressive NHL and could be targeted by selective 
cyclooxygenase-2 inhibition and metronomic chemotherapy. 
Aim of the study: Assessment of the toxicity of metronomic chemotherapy and the response and progression-free survival of relapsed 
diffuse large B cell lymphoma (DLCBL) patients. 
Patients and methods: Forty patients with the diagnosis of relapsed and/or refractory DLCBL. Patients included in this study may have 
received any number of preceding therapies (as long as one had included an anthracycline) and were not candidates for BMT. They 
received cyclophosphamide tab (50 mg p.o. q.d), methotrexate tab (2.5 mg p.o four times per week) and high-dose celecoxib tab (400 
mg p.o. b.i.d.) until disease progression or toxicity. 
Results: All of the 40 patients included (median age, 56 years) were evaluable for response, 52% had a high international prognostic 
index at relapse, with a median follow-up of 8.4 months (range 4–23 months), 32.5% had a partial response and 50% has stable disease. 
Progression-free survival was 12 months. The median response duration was nine months. Treatment protocol was well tolerated with no 
major toxicities. The most common toxicity was fatigue (57.5%), myelo-suppression and gastrointestinal side effects. 
Conclusions: Low-dose cyclophosphamide, methotrexate and high-dose celecoxib are well tolerated and active in pre-treated diffuse 
large cell B lymphoma. Although thrombotic events were not observed during this study, close surveillance for arterial and venous 
thrombotic events is recommended. 
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Diffuse large B cell lymphoma (DLBCL), the most common 
subtype of non-Hodgkin lymphoma (NHL), is an aggressive 
disease with considerable biologic and clinical heterogeneity. 
Standard first-line treatment is combination chemotherapy with 
cyclophosphamide, doxorubicin, vincristine and prednisone 
(CHOP) or an equivalent regimen combined with rituximab (R). 
This results in a complete remission rate of 75–80% and a 3–5-
year progression-free survival (PFS) of 50–80%. The addition of 
R to CHOP chemotherapy has been the most significant step in 
recent years in improving overall survival (OS) and PFS rates. 
Current treatment with CHOP-R results in an improvement in 
PFS and OS by 15–20% compared to CHOP chemotherapy 
alone [1]. 
Despite this major therapeutic advance, a significant proportion 
of patients will relapse or remain refractory to initial chemo-
immunotherapy. The PARMA trial confirmed the place of high-
dose chemotherapy and autologous haematopoietic cell 
transplantation (aHCT) as the optimum salvage treatment. In 
this trial, chemotherapy-sensitive patients were randomized to 
further salvage chemotherapy with cytarabine/platinum-based 
chemotherapy alone, or in combination with aHCT. Event-free 
survival and OS at five years in the transplant arm were 46% 
and 53%, respectively, compared with 12% and 32% in the 
chemotherapy alone arm [2]. 
Numerous salvage chemotherapy regimens have been used to 
treat relapsed or refractory DLBCL patients. The majority are 
based on agents that demonstrate non-cross-resistance to 
those used in primary therapy. Broadly speaking, they can be 
divided into regimens based on ifosfamide, cytarabine/platinum 
or gemcitabine. Studies on salvage therapy have generally 
included all patients with aggressive lymphoma and are not 
restricted to DLBCL subtype [3]. 
Recent data indicate that angiogenesis is important in the 
pathophysiology and prognosis of aggressive histological 
subtypes of NHL. Angiogenesis is a multi-step process that 
leads to the formation of new blood vessels from existing 
vasculature and is associated with the growth and 
dissemination of malignant tumours [4]. Angiogenesis and 
angiogenic factors are increased in most lymphomas. In 
addition, angiogenesis has been associated with adverse 
outcome or more aggressive clinical behaviour in malignant 
lymphoma. However, the role of angiogenesis might vary in 
lymphoma subtypes because of the prognostic value of micro-
vessel density and the different expression of angiogenesis-
related molecules in the various lymphoma subtypes [5].  
Metronomic chemotherapy refers to the frequent, even daily, 
administration of chemotherapeutics at doses significantly 
below the maximum tolerated dose, with no prolonged drug-free 
breaks [6]. 
Much evidence, mostly in vitro, indicates that the 'activated' 
endothelial cells of newly forming blood-vessel capillaries are 
highly and selectively sensitive to very low doses of various 
chemotherapeutic drugs [7]. 
The interesting new findings of Wun et al [8] reveal that human 
Burkitt-type B-cell lymphoma cell lines express elevated levels 
of Cyclooxygenase 2 (COX-2), and this fits with earlier studies 
indicating that B-lineage cells are capable of expressing COX-2. 
COX-2 is a prostaglandin synthase enzyme that has been 
implicated in tumourigenesis. One of the proposed mechanisms 
by which this may occur is by stimulating angiogenesis through 
the production of pro-angiogenic factors, including VEGF, basic 
fibroblast growth factor, platelet-derived growth factor, 
transforming growth factor-h1 and endothelin-1. COX-2 
inhibitors, such as celecoxib, have been shown to reduce the 
incidence of neoplastic lesions in familial adenomatous 
polyposis and therefore may have a role in the treatment of 
established malignancies. Furthermore, COX-2 is over-
expressed in some lymphomas and is of potential prognostic 
importance. These pre-clinical data provide the rationale for 
using low-dose chemotherapy together with a selective COX-2 
inhibitor in the treatment of aggressive NHL [9]. 
 
Patients and methods 
From March 2006 to June 2008, 40 patients with relapsed or 
refractory diffuse large cell lymphoma were enrolled in this 
phase II study. The primary objective was to determine the 
response rate to oral high-dose celecoxib combined with daily 
oral low-dose cyclophosphamide and low-dose methotrexate 
continuous administration in this patient population. The 
secondary objectives were to define the toxicity of the given 
regimen and PFS. 
Patients were considered eligible if they had relapsed after any 
number of preceding therapies (as long as one had included an 
anthracycline) and had a projected life expectancy of >4 
months. 


















Patients who relapsed following autologous haematopoietic 
stem cell transplant were eligible. Patients were excluded from 
the study if they were transplant eligible, receiving concurrent 
chemotheraphy or radiotherapy (including corticosteroids) or 
had received any other antineoplastic therapy within the 
preceding two weeks. Patients with Eastern Cooperative 
Oncology Group performance status of >3, uncontrolled 
hypertension, and unstable cardiovascular or significant renal or 
hepatic disease were also excluded. As celecoxib is a 
sulphonamide, patients with a proven allergy to sulfa drugs 
were also excluded. 
Adequate haematological (haemoglobin count, >85 g/l; absolute 
neutrophil count, >1000/mm
3; platelet count, >75,000/mm
3), 
renal, and hepatic functions were mandatory. All eligible 
patients had at least one bi-dimensionally measurable target 
lesion. Our institutional review board approved this study and 
informed consent was obtained from each patient.   
Pre-treatment evaluations included a complete history and 
physical examination, routine laboratory evaluation, and 
computed tomography of chest, abdomen and pelvis as well as 
bone marrow biopsy. Patients were clinically assessed by 
physical examination and blood work monthly until progression. 
Computed tomography scans were repeated for response 
evaluation every two months or sooner if clinically indicated. 
Patients were followed off-study until death. 
 
Treatment plan  
All patients received celecoxib 400 mg p.o. b.i.d. (with food) and 
cyclophosphamide 50 mg p.o. daily, methotrexate 2.5 mg p.o 
four times per week. In cases of nausea and vomiting (> grade 
3), dyspepsia or abdominal pain or a 50% increase in serum 
creatinine or liver enzymes celecoxib was reduced (200 mg p.o. 
b.i.d. then 100 mg p.o. bid). The need for further dose reduction 
or gastrointestinal bleeding resulted in discontinuation within the 
study. Similarly, cyclophosphamide could be reduced twice (to 
25 mg p.o. daily then 25 mg p.o. alternate days) for grade >3 
neutropenia or thrombocytopenia. No dose escalations were 
permitted. 
Toxicity was assessed according to Common Terminology 
Criteria for Adverse Event v3.0, published 12 December 2003. 
 
Response assessment   
Response to treatment was assessed according to criteria of 
Cheson et al [10]. 
An objective response consisted of complete clinical response, 
complete clinical response unconfirmed or a partial response. 
Progression of disease was determined by an increase of 50% 
in the product of perpendicular diameters of the index lesions or 
the appearance of new lesions. All other patients were 
considered to have stable disease. 
Because anti-angiogenic therapy is cytostatic, and in many pre-
clinical models of metronomic chemotherapy, tumours may 
initially grow before they stabilize and sometimes regress, 
patients were allowed to remain in the study for up to four 
months if radiological or clinical tumour progression was 
asymptomatic and not a threat to vital organ function. 
 
Statistical analysis  
Data were analysed using the SPSS programme for Windows 
version 11. PFS was estimated using the Kaplan-Meier 
estimate. Results were considered significant at the 5% critical 
level (p-value < 0.05) 
 
Results 
This prospective study included 40 patients with refractory or 
relapsed DLBCL who presented at the Menoufia University 
Hospital, Clinical Oncology Department between March 2006 
and June 2008 and were followed up until the end of December 
2008. All patients had measurable disease. Patients received 
low-dose oral cyclophosphamide tab 50 mg daily, methotrexate 
2.5 mg tab four times per week and high-dose celecoxib tab 400 
mg p.o bid. 
 
Patient characteristics 
•  Initial pathologic status:  all patients had 
pathologically diagnosed DLBCL. 
Age and sex distribution: the median age was 56 years 
(range 38–78) with equal male to female ratio (20 male and 20 
female) (see Table 1) 
•  IPI status:  At relapse, 21 patients had a high 
intermediate IPI score (52.5%), six patients (15%) had 
a low intermediate score, three patients (7.5%) had a 
low score, while ten patients (25%) had a high score. 
•  Number of prior chemotherapy regimens only 18 
patients (45%) received this protocol for relapsed 
DLCBL after failure to achieve complete remission with


















Table 1: Age distribution among patients 
 
 
Figure 1: Percentage of fatigue among patients.
CHOP or relapsed after completing their CHOP 
course, while nine patients (22.5%) had received one 
line of chemotherapy for relapsed disease, 11 patients 
(27.5%) had received two lines of treatment and two 
patients (5%) received three lines of treatment for 
relapse. Time from last relapse ranged from one1 to 
ten months with a median of 1.5 months. For patients 
who received one line of treatment for relapse the time 
from last relapse ranged from three to ten months with 
a median of eight months. For patients who received 
two lines of treatment for relapse the time from last 
relapse ranged from one to nine months with a median 
of three months. For the two patients who received 
three lines, the time from the first relapse was one and 
three months, respectively. Here was significant 
correlation between the number of prior protocols and 
the time to relapse; patients who received only one line 
for relapse had a longer time to relapse (p = 0.05). 
Also, there was significant correlation between PFS 
and age of patients (by Kendall's tau test). The number 
of prior chemotherapy protocols given for relapse did 
not (statistically) affect PFS in our study. 
 
oxicity assessment  
g to the National Cancer 
y Criteria for Adverse Events 
T
Toxicity was evaluated accordin
Institute's Common Terminolog
version 3.0. Fatigue was the most important side effect noticed 
in this study(see Figure 1), 13 patients (32.5%) had grade I 
fatigue, nine patients (22.5%) had grade II fatigue, while one 
patient (2.5%) had grade III fatigue. No dose reduction or 
interruption to treatment was necessary except for the patient 
with grade III for whom treatment was interrupted for one week 
then resumed at the usual dose. 
Gastrointestinal toxicities were mild ranging from grade I to 
grade II, with no grade III or IV toxicities observed, except for 
 I 
two patients who had grade III oral mucositis. Both these 
patients had undergone prior whole neck irradiation for 
treatment of cervical lymph nodes; metronomic chemotherapy 
had to be stopped for two weeks until the condition improved. 
Six patients experienced grade I nausea (15%), two patients 
had grade II nausea (5%), while only five patients had grade
vomiting (12.5%). Dyspepsia was observed in ten patients, eight 
patients (20%) had grade I dyspepsia, while two patients (5%)



















Figure 2: Progression-free survival.
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Haematological toxicity
Anaemia was observed in eight pa
anaemia while two (5%) had grade II anaemia. Grade I 
thrombocytopenia was observed in four patients (10%). 
Neutropenia was observed in seven patients, six patients had 
grade I neutropenia (15%), while one patient (2.5%) had grade 
II neutropenia. No dose reduction was needed for 
haematological toxicities. 
Three patients (7.5%) had
to topical corticosteroid and oral antihistamines. 
Three patients had grade I elevated serum crea
>1.5 × ULN) and no dose reduction of celecoxib was necessary. 
One patient had grade II elevated serum creatinine (1.5 - 3 × 
ULN) and the celecoxib dose was reduced to 200 mg b.i.d. 
Two patients had grade I oedema, which responded to a short
course of diuretics with no treatment interruption. 
There was no hepatic toxicity reported in this stu
elevated liver enzymes or elevated bilirubin levels. 
Thirteen patients (32.5%
responses were achieved in this study. Twenty patients (50%) 
had stable disease. Seven patients (17.5%) progressed, four of 
whom died due to progressive disease while the other three 
were shifted to another line of chemotherapy. For the whole 
study population, time from diagnosis of initial disease (i.e. 
primary diagnosis of lymphoma—before relapse or resistance to 
CHOP) until last follow-up ranged from five to 85 months with a 
median of 18 months. 
Among the patients w
progressed while on therapy at a median of nine months, with a 
range of 6–12 months. Eight patients with stable disease 
developed a progressive course at a median of 8.5 months with 
a range of 5–23 months. 
Patients who progresse




The median actuarial PFS was 12 
16.15), (see Figure 2) 


















There was a significant correlation between PFS and age (p-
value 0.04). 
There was no significant correlation between PFS and time from 
last relapse, number of prior lines of chemotherapy or time from 
last treatment. 
Also, there was no significant correlation between IPI score and 
PFS (p = 0.07). 
 
Discussion 
Targeting angiogenesis has also been investigated in the 
Southwest Oncology Group S0108 study of the anti-VEGF 
monoclonal antibody, bevacizumab, in patients with relapsed 
DLBCL. A clinical non-progression rate of 25% was observed 
for the 51 patients in this study, with a median time to 
progression of five months (range 4–18 months) [11]. 
In our study, we have shown that the combination of continuous 
low-dose cyclophosphamide, methotrexate with high-dose 
celecoxib resulted in a response rate of 32.5% in a group of pre-
treated patients with relapsed DLBCL. The combination was 
well tolerated, with a low incidence of haematological, 
gastrointestinal and renal toxicity. 
There is only one published study regarding the use of 
metronomic chemotherapy in treatment of relapsed NHL, by 
Buckstein  et al [9] in which 32 patients with relapsed or 
refractory NHL were enrolled to receive high-dose celecoxib 
400 mg b.i.d daily and low-dose cyclophosphamide 50 mg p.o 
daily. Only 20 patients had relapsed or refractory DLBCL, others 
had anaplastic lymphoma, T-cell lymphoma or transformed 
follicular lymphoma. Most patients were heavily pre-treated, with 
a median of three prior chemotherapy regimens (range 1–7). 
Eleven patients (34%) had relapsed after autologous 
haematopoietic stem cell transplant. 
In our study, we added methotrexate tab 2.5 mg four times per 
week, all patients had relapsed or refractory DLBCL with no
other pathological types, in addition none of our patients had 
received aHCT. 
None of our patients achieved complete remission while 
(32.5%) and (50%) achieved partial response and stable 
disease, respectively. 
In our study, the median actuarial PFS was 12 months (95% CI, 
7.85–16.15) compared to the study of Buckstein et al [9] in 
which the median actuarial PFS was 4.7 months (95% CI, 2.5–
9.2). 
In our study, only three patients had grade I skin rash, which 
developed months after initiation of treatment and responded to 
anti-allergic treatments; no interruption of the programme was 
needed. Fatigue was a common side effect; 13 patients (32.5%) 
had grade I fatigue, nine patients (22.5%) had grade II fatigue, 
while one patient (2.5%) had grade III fatigue. No thrombotic 
events were observed in our study. 
 
Conclusion 
We conclude that metronomic chemotherapy can be used for 
patients with relapsed and or refractory DLBCL with reasonable 
outcome and acceptable toxicity. Standard lines such as HST 
and chemo-immunotherapy combinations should be explored 
prior to a decision on metronomic chemotherapy.  
 
Recommendation 
A longer follow up is recommended to evaluate the late 
toxicities of metronomic chemotherapy schedule. Although there 
were no thromboembolic manifestations recorded in this study, 
it is important to closely monitor the patients for these events as 
they are exposed to high levels of celecoxib. 
We suggest a study involving a larger number of patients and to 
correlate clinical response with VEGF blood levels and also to 
determine COX-2 receptor status before and during treatment to 
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